Xalkori® (crizotinib): Inclusion of a new warning regarding cardiac failure

Kadar pengguna: 3 / 5

bintang aktifbintang aktifbintang aktifBintang tidak aktifBintang tidak aktif

Date: 30 March 2016



The package inserts of Xalkori® will be updated with safety information on the risk of cardiac failure following a safety review of clinical trial data and post-marketing reports. There have been reports of cardiac failure, in some cases fatal, in those receiving crizotinib, involving patients with or without pre-existing cardiac disorders. Patients treated with crizotinib should be monitored for signs and symptoms of cardiac failure, and measures such as dosing interruption, reduction or discontinuation should be considered if such symptoms are identified. For further details, please refer to the Direct Healthcare Professional Communication (DHPC) issued by Pfizer (Malaysia) Sdn. Bhd., in agreement with NPCB.


National Pharmaceutical Regulatory Agency (NPRA)

Lot 36, Jalan Universiti (Jalan Prof Diraja Ungku Aziz), 46200 Petaling Jaya, Selangor, Malaysia.

  • Phone: +603-7883 5400




The Government of Malaysia and the National Pharmaceutical Regulatory Agency are not responsible for any loss or damage caused by the usage of any information obtained from this website.

Mobile Web :

Site Last Modified

  • Last Modified: Jumaat 12 Julai 2024, 15:24:37.
© Copyright 2018 . All Rights Reserved National Pharmaceutical Regulatory Agency NPRA


Menu Utama